Company intelligence / Profile preview

Broadcast News

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Broadcast is a Flagship Pioneering-founded biotechnology company focused on developing a new class of programmable medicines. The company leverages advanced RNA technology to 'broadcast' therapeutic instructions directly to specific cells within the body, aiming to treat a wide range of diseases by modulating cellular behavior. By utilizing a platform that combines synthetic biology with sophisticated delivery mechanisms, Broadcast seeks to overcome traditional limitations in drug targeting and efficacy. The company is currently in the early stages of building its pipeline and establishing its core technology within the Flagship ecosystem.

Modalities: mRNA-based drugsProgrammable medicinesRNA therapy
Industry: Biotech

Beyond the preview

Go deeper on Broadcast News.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Broadcast News.

Explore the full profile